ArticleFrontiers in microbiology2023
Construction of
Article in Frontiers in microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- Genomic and pan-genomic analyses of Bacillus subtilis B13 provide insights into biosynthetic potential and genetic traits associated with environmental adaptation.Antonie van Leeuwenhoek · 2026Article
- A One Health Perspective onMicroorganisms · 2026Review
- Optimization Strategy of Expression Vectors and Regulatory Elements for Enhanced Protein Production inInternational journal of molecular sciences · 2025Review
- Production of the Antimicrobial Roseoflavin With Genetically Engineered Corynebacterium glutamicum.Microbial biotechnology · 2025Article
- Xylose Metabolism and Transport inJournal of microbiology and biotechnology · 2025Review
- Molecular imaging uncovers growth media influence on biofilms' EPS production.Frontiers in chemistry · 2025Article
- Current Knowledge on CRISPR Strategies Against Antimicrobial-Resistant Bacteria.Antibiotics (Basel, Switzerland) · 2024Review
- Strategies for improving fengycin production: a review.Microbial cell factories · 2024Review
- The role ofFrontiers in microbiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fengycin is a multifunctional peptide antibiotic produced mainly by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.